The stock was down as much as 10% Thursday, but pared those losses by mid-morning to just 0.72% to $275.07 a share.
Earnings per share for the fourth quarter of the company's fiscal year 2019 came in at $1.04, in line with analysts estimates. But revenue was $207 million, missing analysts expectations of $217.64 million. Total Impella heart pump revenue, which accounts for the majority of revenue, rose 19% year-over-year to $199.5 million. U.S. Impella revenue rose to 16% to $169.7 million. While the growth rates were solid, they fell short of expectations.
"Q4 did not meet our expectations," said chairman, president and CEO Michael R. Minogue. "I take full responsibility for our disappointing performance given a soft March, and we have already initiated a plan of action to correct the course."
Management guided for total fiscal year 2020 revenue to be in a range between $900 million and $945 million, below consensus estimates for 2020 revenue of $988.6 million. GAAP operating margin for 2020 was guided to be between 29% and 31%. Analysts are looking for an operating margin of 31.1%.
The stock is down 13.3% this year.